Targeting the activin receptor 1C on CD4+ T cells for cancer immunotherapy

References

• Risbridger GP, Schmitt JF, Robertson DM. Activins and inhibins in endocrine and other tumors. Endocr Rev. 2001;22(6):836–12. doi: 10.1210/edrv.22.6.0450
   PubMed Web of Science ®Google Scholar
• Jörnvall H, Reissmann E, Andersson O, Mehrkash M, Ibáñez CF. ALK7, a receptor for nodal, is dispensable for embryogenesis and left-right patterning in the mouse. Mol Cell Biol. 2004;24(21):9383–9389. doi: 10.1128/mcb.24.21.9383-9389.2004
   PubMed Web of Science ®Google Scholar
• Bonomi L, Brown M, Ungerleider N, Muse M, Matzuk MM, Schneyer A. Activin B regulates islet composition and islet mass but not whole body glucose homeostasis or insulin sensitivity. Am J Physiol Endocrinol Metab. 2012;303(5):E587–596. doi: 10.1152/ajpendo.00177.2012
   PubMed Web of Science ®Google Scholar
• Lu AQ, Popova EY, Barnstable CJ. Activin signals through SMAD2/3 to increase photoreceptor precursor yield during embryonic stem cell differentiation. Stem Cell Rep. 2017;9(3):838–852. doi: 10.1016/j.stemcr.2017.06.021
   PubMed Web of Science ®Google Scholar
• Makanji Y, Zhu J, Mishra R, Holmquist C, Wong WPS, Schwartz NB, Mayo KE, Woodruff TK. Inhibin at 90: from discovery to clinical application, a historical review. Endocr Rev. 2014;35(5):747–794. doi: 10.1210/er.2014-1003
   PubMed Web of Science ®Google Scholar
• Tsuchida K, Nakatani M, Yamakawa N, Hashimoto O, Hasegawa Y, Sugino H. Activin isoforms signal through type I receptor serine/threonine kinase ALK7. Mol Cell Endocrinol. 2004;220(1–2):59–65. doi: 10.1016/j.mce.2004.03.009
   PubMed Web of Science ®Google Scholar
• Goebel EJ, Ongaro L, Kappes EC, Vestal K, Belcheva E, Castonguay R, Kumar R. The orphan ligand, activin C, signals through activin receptor-like kinase 7. Elife. 2022;11. doi: 10.7554/eLife.78197
   PubMed Web of Science ®Google Scholar
• Heldin CH, Moustakas A. Signaling receptors for TGF-β family members. Cold Spring Harb Perspect Biol. 2016;8(8):a022053. doi: 10.1101/cshperspect.a022053
   PubMed Web of Science ®Google Scholar
• Tsuchida K, Nakatani M, Hitachi K, Uezumi A, Sunada Y, Ageta H, Inokuchi K. Activin signaling as an emerging target for therapeutic interventions. Cell Commun Signal. 2009;7(1):15. doi: 10.1186/1478-811x-7-15
   PubMedGoogle Scholar
• Cui X, Shang, S., Lv, X., Zhao, J., Qi, Y., Liu, Z. Perspectives of small molecule inhibitors of activin receptor‑like kinase in anti‑tumor treatment and stem cell differentiation (review). Mol Med Rep. 2019;19:5053–5062. doi: 10.3892/mmr.2019.10209
   PubMed Web of Science ®Google Scholar
• Iizuka-Koga M, Nakatsukasa, H., Ito, M., Akanuma, T., Lu, Q., Yoshimura, A. Induction and maintenance of regulatory T cells by transcription factors and epigenetic modifications. J Autoimmun. 2017;83:113–121. doi: 10.1016/j.jaut.2017.07.002
   PubMed Web of Science ®Google Scholar
• Colamatteo A, Carbone F, Bruzzaniti S, Galgani M, Fusco C, Maniscalco GT, Di Rella F, de Candia P, De Rosa V. Molecular mechanisms controlling Foxp3 expression in health and autoimmunity: from epigenetic to post-translational regulation. Front Immunol. 2019;10:3136. doi: 10.3389/fimmu.2019.03136
   PubMed Web of Science ®Google Scholar
• Huber S, Stahl FR, Schrader J, Luth S, Presser K, Carambia A, Flavell RA, Werner S, Blessing M, Herkel J, et al. Activin a promotes the TGF-β-induced conversion of CD4+CD25− T cells into Foxp3+ induced regulatory T cells. J Immunol. 2009;182(8):4633–4640. doi: 10.4049/jimmunol.0803143
   PubMed Web of Science ®Google Scholar
• Halvorsen EC, Mahmoud SM, Bennewith KL. Emerging roles of regulatory T cells in tumour progression and metastasis. Cancer Metastasis Rev. 2014;33:1025–1041. doi: 10.1007/s10555-014-9529-x
   PubMed Web of Science ®Google Scholar
• Li C, Jiang P, Wei S, Xu X, Wang J. Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Mol Cancer. 2020;19(1):116. doi: 10.1186/s12943-020-01234-1
   PubMed Web of Science ®Google Scholar
• Wei X, Zhang J, Gu Q, Huang M, Zhang W, Guo J, Zhou X. Reciprocal expression of IL-35 and IL-10 defines two distinct effector Treg subsets that are required for maintenance of immune tolerance. Cell Rep. 2017;21(7):1853–1869. doi: 10.1016/j.celrep.2017.10.090
   PubMed Web of Science ®Google Scholar
• Overacre-Delgoffe AE, Chikina, M., Dadey, R. E., Yano, H., Brunazzi, E. A., Shayan, G. Interferon-γ drives Treg fragility to promote anti-tumor immunity. Cell. 2017;169(6):1130–1141.e1111. doi: 10.1016/j.cell.2017.05.005
   PubMed Web of Science ®Google Scholar
• Carmenate T, Ortíz Y, Enamorado M, García-Martínez K, Avellanet J, Moreno E, Graça L, León K. Blocking IL-2 signal in vivo with an IL-2 Antagonist Reduces tumor growth through the control of regulatory T cells. J Immunol. 2018;200(10):3475–3484. doi: 10.4049/jimmunol.1700433
   PubMed Web of Science ®Google Scholar
• Fisher SA, Aston WJ, Chee J, Khong A, Cleaver AL, Solin JN, Ma S, Lesterhuis WJ, Dick I, Holt RA, et al. Transient Treg depletion enhances therapeutic anti-cancer vaccination. Immunity Inflam & Disease. 2017;5(1):16–28. doi: 10.1002/iid3.136
   PubMed Web of Science ®Google Scholar
• Morianos I, Papadopoulou G, Semitekolou M, Xanthou G. Activin-A in the regulation of immunity in health and disease. J Autoimmun. 2019;104:102314. doi: 10.1016/j.jaut.2019.102314
   PubMed Web of Science ®Google Scholar
• Bertolino P, Holmberg R, Reissmann E, Andersson O, Berggren P-O, Ibáñez CF. Activin B receptor ALK7 is a negative regulator of pancreatic β-cell function. Proc Natl Acad Sci U S A. 2008;105(20):7246–7251. doi: 10.1073/pnas.0801285105
   PubMed Web of Science ®Google Scholar
• Michael IP, Saghafinia S, Tichet M, Zangger N, Marinoni I, Perren A, Hanahan D. ALK7 signaling manifests a homeostatic tissue barrier that is abrogated during Tumorigenesis and metastasis. Dev Cell. 2019;49(3):409–424.e406. doi: 10.1016/j.devcel.2019.04.015
   PubMed Web of Science ®Google Scholar
• Wu B, Zhang, S., Guo, Z., Bi, Y., Zhou, M., Li, P. Wan, Y. Y. The TGF-β superfamily cytokine activin-A is induced during autoimmune neuroinflammation and drives pathogenic Th17 cell differentiation. Immunity. 2021;54(2):308–323.e306. doi: 10.1016/j.immuni.2020.12.010
   PubMed Web of Science ®Google Scholar
• Kita A, Kasamatsu A, Nakashima D, Endo-Sakamoto Y, Ishida S, Shimizu T, Kimura Y, Miyamoto I, Yoshimura S, Shiiba M, et al. Activin B regulates adhesion, invasiveness, and migratory activities in oral cancer: a potential biomarker for metastasis. J Cancer. 2017;8(11):2033–2041. doi: 10.7150/jca.18714
   PubMed Web of Science ®Google Scholar
• Jones CP, Gregory LG, Causton B, Campbell GA, Lloyd CM. Activin a and TGF-β promote TH9 cell–mediated pulmonary allergic pathology. J Allergy Clin Immunol. 2012;129(4):1000–1010.e1003. doi: 10.1016/j.jaci.2011.12.965
   PubMed Web of Science ®Google Scholar
• Ni X, Tao J, Barbi J, Chen Q, Park BV, Li Z, Zhang N, Lebid A, Ramaswamy A, Wei P, et al. YAP is essential for Treg-mediated suppression of antitumor immunity. Cancer Discov. 2018;8(8):1026–1043. doi: 10.1158/2159-8290.Cd-17-1124
   PubMed Web of Science ®Google Scholar
• Feldman JP, Goldwasser R, Mark S, Schwartz J, Orion I. A mathematical model for tumor volume evaluation using two-dimensions. J Appl Quant Meth. 2009;4:455–462.
   Google Scholar
• Sápi J, Kovács L, Drexler DA, Kocsis P, Gajári D, Sápi Z. Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy. PLoS ONE. 2015;10(11):e0142190. doi: 10.1371/journal.pone.0142190
   PubMed Web of Science ®Google Scholar
• Chen L, Zhang W, Liang H-F, Zhou Q-D, Ding Z-Y, Yang H-Q, Liu W-B, Wu Y-H, Man Q, Zhang B-X, et al. Activin a induces growth arrest through a SMAD- dependent pathway in hepatic progenitor cells. Cell Commun Signal. 2014;12(1):18. doi: 10.1186/1478-811x-12-18
   PubMedGoogle Scholar
• Moustakas A, Souchelnytskyi S, Heldin CH. Smad regulation in TGF-β signal transduction. J Cell Sci. 2001;114(24):4359–4369. doi: 10.1242/jcs.114.24.4359
   PubMed Web of Science ®Google Scholar
• Khalil AM, Dotimas H, Kahn J, Lamerdin JE, Hayes DB, Gupta P, Franti M. Differential binding activity of TGF- family proteins to select TGF- receptors. J Pharmacol Exp Ther. 2016;358(3):423–430. doi: 10.1124/jpet.116.232322
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi: 10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Schmiedel BJ, Singh D, Madrigal A, Valdovino-Gonzalez AG, White BM, Zapardiel-Gonzalo J, Ha B, Altay G, Greenbaum JA, McVicker G, et al. Impact of genetic polymorphisms on human immune cell gene expression. Cell. 2018;175(6):1701–1715 e1716. doi: 10.1016/j.cell.2018.10.022
   PubMed Web of Science ®Google Scholar
• Walentowicz P, Krintus M, Sadlecki P, Grabiec M, Mankowska-Cyl A, Sokup A, Walentowicz-Sadlecka M. Serum inhibin a and inhibin B levels in epithelial ovarian cancer patients. PLoS ONE. 2014;9(3):e90575. doi: 10.1371/journal.pone.0090575
   PubMed Web of Science ®Google Scholar
• Antsiferova M, Huber M, Meyer M, Piwko-Czuchra A, Ramadan T, MacLeod AS, Havran WL, Dummer R, Hohl D, Werner S, et al. Activin enhances skin tumourigenesis and malignant progression by inducing a pro-tumourigenic immune cell response. Nat Commun. 2011;2(1):576. doi: 10.1038/ncomms1585
   PubMedGoogle Scholar
• Bondestam J, Huotari M-A, Morén A, Ustinov J, Kaivo-Oja N, Kallio J, Horelli-Kuitunen N, Aaltonen J, Fujii M, Moustakas A, et al. cDNA cloning, expression studies and chromosome mapping of human type I serine/threonine kinase receptor ALK7 (ACVR1C). Cytogenet Cell Genet. 2001;95(3–4):157–162. doi: 10.1159/000059339
   PubMedGoogle Scholar
• Zhao M, Okunishi K, Bu Y, Kikuchi O, Wang H, Kitamura T, Izumi T. Targeting activin receptor–like kinase 7 ameliorates adiposity and associated metabolic disorders. JCI Insight. 2023;8(4). doi: 10.1172/jci.insight.161229
   Web of Science ®Google Scholar